Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03513952
Title Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Atezolizumab + CYT107

Atezolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Kaiser Permanente-Riverside Recruiting Riverside California 92505 United States Details
Moffitt Cancer Center Recruiting Tampa Florida 33612 United States Details
Straub Clinic and Hospital Recruiting Honolulu Hawaii 96813 United States Details
University of Hawaii Cancer Center Suspended Honolulu Hawaii 96813 United States Details
University of Chicago Comprehensive Cancer Center Suspended Chicago Illinois 60637 United States Details
East Jefferson General Hospital Recruiting Metairie Louisiana 70006 United States Details
Washington University School of Medicine Recruiting Saint Louis Missouri 63110 United States Details
Roswell Park Cancer Institute Recruiting Buffalo New York 14263 United States Details
Seattle Cancer Care Alliance Recruiting Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field